| 形态 | Liquid |
|---|
| 宿主种属 | Human |
|---|
| 克隆性 | Monoclonal |
|---|
| 抗体亚型 | IgG1-kappa |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| 浓度 | 1mg/ml |
|---|
| 内毒素水平 | Please contact the lab for this information. |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 种属反应性 | Human |
|---|
| 靶标 | Disintegrin and metalloproteinase domain-containing protein 9, Meltrin-gamma, ADAM9, MDC9, MLTNG, ADAM 9, Metalloprotease/disintegrin/cysteine-rich protein 9, Cellular disintegrin-related protein, KIA |
|---|
| 储存缓冲液 | 0.01M PBS, pH 7.4. |
|---|
| 稳定性和储存 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| 表达系统 | Mammalian Cells |
|---|
| 登录号 | Q13443 |
|---|
| 背景信息 | Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models.
|
|---|
| 别名 | 2642078-60-0 |
|---|
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
|---|